Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue
Product sales	$ 681,127	$ 1,028,146	$ 1,415,629	$ 1,975,365
Laboratory services	15,850	29,674	31,955	159,094
Collaboration revenue	6,233	125,000	27,397	125,000
Total revenue	703,210	1,182,820	1,474,981	2,259,459
Operating expenses
Cost of products sold	392,791	337,020	817,741	682,987
Cost of services	78,763	161,222	178,996	476,931
Research and development	1,762,234	2,333,584	3,884,749	4,287,013
General and administrative	1,750,018	1,777,054	3,719,234	3,315,100
Sales and marketing	909,402	1,588,553	2,014,988	2,987,988
Total operating expenses	4,893,208	6,197,433	10,615,708	11,750,019
Operating loss	(4,189,998)	(5,014,613)	(9,140,727)	(9,490,560)
Other expense
Interest and other income/(expense)	22	(3,874)	43	(3,699)
Interest expense	(53,813)	(26,649)	(83,657)	(68,383)
Foreign currency transaction gains/(losses)	8,998	(7,766)	11,618	3,562
Changes in fair value of warrant and conversion option liabilities	26,744	0	26,744	0
Total other expense	(18,049)	(38,289)	(45,252)	(68,520)
Loss before income taxes	(4,208,047)	(5,052,902)	(9,185,979)	(9,559,080)
Provision for income taxes	0	0	0	0
Net loss	(4,208,047)	(5,052,902)	(9,185,979)	(9,559,080)
Preferred stock dividends and beneficial conversion	0	(332,550)	0	(332,550)
Net loss available to common stockholders	$ (4,208,047)	$ (5,385,452)	$ (9,185,979)	$ (9,891,630)
Net loss per common share - basic and diluted	$ (0.15)	$ (0.37)	$ (0.34)	$ (0.74)
Weighted average shares outstanding - basic and diluted	28,210,657	14,522,097	27,161,931	13,545,519
Net loss	$ (4,208,047)	$ (5,052,902)	$ (9,185,979)	$ (9,559,080)
Other comprehensive (loss)/income - foreign currency translation	(3,834)	1,498	(7,591)	387
Comprehensive loss	$ (4,211,881)	$ (5,051,404)	$ (9,193,570)	$ (9,558,693)